Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Malcolm A Smith

Showing results (31-40 of 188) with videos related to

Pageof 19
Sort By:
Pediatric Blood & Cancer|October 30, 2013
Initial testing (stage 1) of the topoisomerase II inhibitor pixantrone, by the pediatric preclinical testing programRaushan T Kurmasheva, C Patrick Reynolds, Min H Kang, et al.
Future Medicinal Chemistry|March 24, 2011
Institutional profile: Developing and evaluating new drugs for cancer treatment: perspectives from the US National Cancer InstituteEdward L Trimble, Jeffrey S Abrams, Sherry S Ansher, et al.
Pediatric Blood & Cancer|September 19, 2017
Initial testing (stage 1) of M6620 (formerly VX-970), a novel ATR inhibitor, alone and combined with cisplatin and melphalan, by the Pediatric Preclinical Testing ProgramRaushan T Kurmasheva, Dias Kurmashev, C Patrick Reynolds, et al.
Pediatric Blood & Cancer|June 11, 2014
Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing programE Anders Kolb, Richard Gorlick, Catherine A Billups, et al.
Pediatric Blood & Cancer|September 11, 2013
Initial testing (Stage 1) of TAK-701, a humanized hepatocyte growth factor binding antibody, by the Pediatric Preclinical Testing ProgramPeter J Houghton, Raushan T Kurmasheva, E Anders Kolb, et al.
Pediatric Blood & Cancer|August 28, 2021
In vivo evaluation of the lysine-specific demethylase (KDM1A/LSD1) inhibitor SP-2577 (Seclidemstat) against pediatric sarcoma preclinical models: A report from the Pediatric Preclinical Testing Consortium (PPTC)Raushan T Kurmasheva, Stephen W Erickson, Ruolan Han, et al.
Pediatric Blood & Cancer|September 10, 2014
Efficacy of CPX-351, (cytarabine:daunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing ProgramHernan Carol, Mannie M Y Fan, Troy O Harasym, et al.
Pediatric Blood & Cancer|February 9, 2012
Evaluation of arsenic trioxide by the pediatric preclinical testing program with a focus on Ewing sarcomaMalcolm A Smith, Min H Kang, C Patrick Reynolds, et al.
Pediatric Blood & Cancer|April 24, 2019
Preclinical activity of the antibody-drug conjugate denintuzumab mafodotin (SGN-CD19A) against pediatric acute lymphoblastic leukemia xenograftsLuke Jones, Hannah McCalmont, Kathryn Evans, et al.
Pediatric Blood & Cancer|August 25, 2016
Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing ProgramRaushan T Kurmasheva, Melissa Sammons, Edward Favours, et al.
Pageof 19

Showing results (31-40 of 188) with videos related to

Sort By:
Pageof 19
Pediatric Blood & Cancer|October 30, 2013
Initial testing (stage 1) of the topoisomerase II inhibitor pixantrone, by the pediatric preclinical testing programRaushan T Kurmasheva, C Patrick Reynolds, Min H Kang, et al.
Future Medicinal Chemistry|March 24, 2011
Institutional profile: Developing and evaluating new drugs for cancer treatment: perspectives from the US National Cancer InstituteEdward L Trimble, Jeffrey S Abrams, Sherry S Ansher, et al.
Pediatric Blood & Cancer|September 19, 2017
Initial testing (stage 1) of M6620 (formerly VX-970), a novel ATR inhibitor, alone and combined with cisplatin and melphalan, by the Pediatric Preclinical Testing ProgramRaushan T Kurmasheva, Dias Kurmashev, C Patrick Reynolds, et al.
Pediatric Blood & Cancer|June 11, 2014
Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing programE Anders Kolb, Richard Gorlick, Catherine A Billups, et al.
Pediatric Blood & Cancer|September 11, 2013
Initial testing (Stage 1) of TAK-701, a humanized hepatocyte growth factor binding antibody, by the Pediatric Preclinical Testing ProgramPeter J Houghton, Raushan T Kurmasheva, E Anders Kolb, et al.
Pediatric Blood & Cancer|August 28, 2021
In vivo evaluation of the lysine-specific demethylase (KDM1A/LSD1) inhibitor SP-2577 (Seclidemstat) against pediatric sarcoma preclinical models: A report from the Pediatric Preclinical Testing Consortium (PPTC)Raushan T Kurmasheva, Stephen W Erickson, Ruolan Han, et al.
Pediatric Blood & Cancer|September 10, 2014
Efficacy of CPX-351, (cytarabine:daunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing ProgramHernan Carol, Mannie M Y Fan, Troy O Harasym, et al.
Pediatric Blood & Cancer|February 9, 2012
Evaluation of arsenic trioxide by the pediatric preclinical testing program with a focus on Ewing sarcomaMalcolm A Smith, Min H Kang, C Patrick Reynolds, et al.
Pediatric Blood & Cancer|April 24, 2019
Preclinical activity of the antibody-drug conjugate denintuzumab mafodotin (SGN-CD19A) against pediatric acute lymphoblastic leukemia xenograftsLuke Jones, Hannah McCalmont, Kathryn Evans, et al.
Pediatric Blood & Cancer|August 25, 2016
Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing ProgramRaushan T Kurmasheva, Melissa Sammons, Edward Favours, et al.
Pageof 19